Suppr超能文献

验证 FibroScan 测量的受控衰减参数作为代谢紊乱评估的新型替代标志物。

Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement.

机构信息

Department of Endocrinology and Diabetes Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Centro Hospitalar Conde de S Januário, Macau, Macau SAR, China.

出版信息

Front Endocrinol (Lausanne). 2022 Jan 31;12:739875. doi: 10.3389/fendo.2021.739875. eCollection 2021.

Abstract

BACKGROUND/OBJECTIVES: Renaming non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) suggests a shift of emphasis to the accompanying metabolic disturbance. Controlled attenuation parameter (CAP) measured by FibroScan has been shown to be correlated with hepatic steatosis. We aim to validate its usefulness as a novel surrogate marker for evaluating metabolic derangement.

SUBJECTS/METHODS: Volunteers were recruited from medical staff at our hospital to undergo CAP measurements. Anthropometrics, CAP, and laboratory assessments for metabolic profiles and insulin resistance were collected. CAP < 238 dB/m denoted no hepatic steatosis, 238 ≤ CAP ≤ 259 dB/m denoted mild, 260 ≤ CAP ≤ 291 dB/m denoted moderate, and CAP > 291 dB/m denoted severe hepatic steatosis according to previous reports.

RESULTS

Data of 824 participants were included for analysis. The age was 53.2 ± 15.4 years, body mass index (BMI) was 23.6 ± 3.1 kg/m, 24.4% were male subjects, and 22.0% met the criteria for metabolic syndrome (MetS). Taking the group with CAP < 238 dB/m as control, subjects with mild, moderate, and severe hepatic steatosis had increased odds of MetS by 3.51-, 3.32-, and 5.12-fold, respectively, after adjusting for multiple confounders ( = 0.020). Metabolic profiles, insulin resistance, and presence of MetS were similar between normal-weight subjects with CAP ≥ 238 dB/m and overweight subjects with CAP < 238 dB/m. Even in subjects with no MetS components, those with CAP ≥ 238 dB/m had higher BMI, waist circumferences, uric acid, triglyceride, white blood cell count, and insulin resistance, whereas lower adiponectin and estimated glomerular filtration rate. Waist circumference [OR 1.11 (1.04, 1.18), = 0.001] and homeostatic model assessment of insulin resistance (HOMA-IR) [OR 2.39 (1.18, 4.83), = 0.016] were predictive of hepatic steatosis according to CAP ≥ 238 dB/m.

CONCLUSIONS

CAP is a convenient, sensitive, and non-invasive indicator for metabolic derangement. Prospective studies are needed to further validate its usefulness as a surrogate marker for the transition of metabolic status over time.

摘要

背景/目的:将非酒精性脂肪性肝病(NAFLD)更名为代谢相关脂肪性肝病(MAFLD),表明人们对伴随的代谢紊乱的关注有所转变。FibroScan 测量的受控衰减参数(CAP)已被证明与肝脂肪变性相关。我们旨在验证其作为评估代谢紊乱的新型替代标志物的有效性。

受试者/方法:从我院医务人员中招募志愿者进行 CAP 测量。收集人体测量学、CAP 和代谢特征及胰岛素抵抗的实验室评估数据。根据之前的报告,CAP<238dB/m 表示无肝脂肪变性,238dB/m≤CAP≤259dB/m 表示轻度,260dB/m≤CAP≤291dB/m 表示中度,CAP>291dB/m 表示严重肝脂肪变性。

结果

共纳入 824 名参与者的数据进行分析。年龄为 53.2±15.4 岁,体重指数(BMI)为 23.6±3.1kg/m,24.4%为男性,22.0%符合代谢综合征(MetS)标准。以 CAP<238dB/m 的组为对照组,调整多重混杂因素后,CAP 轻度、中度和重度肝脂肪变性组发生 MetS 的比值比(OR)分别为 3.51、3.32 和 5.12( = 0.020)。在没有 MetS 成分的正常体重受试者中,CAP≥238dB/m 与 CAP<238dB/m 的超重受试者的代谢特征、胰岛素抵抗和 MetS 存在差异。即使在没有 MetS 成分的受试者中,CAP≥238dB/m 的受试者 BMI、腰围、尿酸、甘油三酯、白细胞计数和胰岛素抵抗更高,而脂联素和估算肾小球滤过率(eGFR)更低。腰围[OR 1.11(1.04,1.18), = 0.001]和稳态模型评估的胰岛素抵抗(HOMA-IR)[OR 2.39(1.18,4.83), = 0.016]是根据 CAP≥238dB/m 预测肝脂肪变性的因素。

结论

CAP 是一种方便、敏感和非侵入性的代谢紊乱指标。需要前瞻性研究进一步验证其作为代谢状态随时间变化的替代标志物的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e0/8841525/b3b8bb8b5dd1/fendo-12-739875-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验